drugset
drugset / Trial / NCT06193031

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy Participants

NCT06193031 ↗

Phase 1 Completed 24 enrolled Insmed Incorporated
RandomizedSequentialQuadruple-blindTreatment

Summary

The primary purpose of this study is to determine the safety and tolerability of escalating doses of C16TR for inhalation in healthy participants.

Timeline

Start
2015-11-17
Primary completion
2015-12-18
Completion
2015-12-18

Drugs

EvaluationDrugModalityDoseRoute
Subject C16TR Unknown — Inhaled
Background Treprostinil Other / unclassified — Inhaled

Indications

No indication recorded.